Karyopharm Therapeutics (NASDAQ: KPTI) Q2 Earnings: Revenue Beat, EPS Miss, and Strategic Oncology Focus

• Revenue Beat: Karyopharm Therapeutics exceeded Q2 revenue estimates, driven by strong XPOVIO® sales.
• EPS Miss & Financial Challenges: Despite revenue growth, the company reported a larger-than-expected EPS loss and faces challenges indicated by negative debt-to-equity and enterprise value-to-operating cash flow ratios.
• Strategic Prioritization: Karyopharm is refocusing on its Myelofibrosis program and advancing its Selinexor drug, reaffirming full-year revenue guidance.

Karyopharm Therapeutics (NASDAQ: KPTI) is a biopharmaceutical company that focuses on creating new treatments for cancer. The company is currently developing therapies for conditions such as Myelofibrosis and Multiple Myeloma. This work places it in a competitive and innovative area of medicine, where it aims to address unmet patient needs.

On August 13, 2026, Karyopharm reported its second-quarter earnings results. The company announced strong revenue of $33.43 million, which surpassed the estimated $32.19 million. This total revenue figure included $30.8 million in U.S. net product revenue from its drug XPOVIO®, a key product for Karyopharm.

Despite the strong revenue, the company's earnings per share (EPS) came in at -$2.32. This figure missed the analyst consensus estimate of -$1.37, showing a larger loss per share than expected. This loss is also reflected in Karyopharm's negative price-to-earnings (P/E) ratio of -0.16.

Other financial metrics also point to challenges. Karyopharm has a debt-to-equity ratio of -0.08, which can indicate that the company's liabilities are greater than its assets. Additionally, its enterprise value-to-operating cash flow ratio is -0.12, suggesting negative cash flow from its core business activities over the past year.

Looking ahead, Karyopharm reaffirmed its full-year 2026 revenue guidance of $130 million to $150 million. The company is prioritizing its Myelofibrosis program after a trial in endometrial cancer did not meet its main goal, as highlighted by PRNewsWire. An important regulatory submission for its Selinexor drug remains on track.